In 1L unresectable or mHCC

More Than Double the Overall Response Rate vs Sorafenib*

TECENTRIQ + Avastin® (bevacizumab) reduced tumor burden vs sorafenib 1


  • ORR as assessed by HCC mRECIST was 33% with TECENTRIQ + Avastin (n=112/336; 95% CI, 28, 39) vs 13% with sorafenib (n=21/165; 95% CI, 8, 19)
    • CR: 11% vs 1.8%
    • PR: 22% vs 11%
  • At the time of analysis, median DoR was not yet reached with TECENTRIQ + Avastin (95% CI, NE, NE; range: 1.3+, 13.4+ mo) vs 6.3 months with sorafenib (95% CI, 4.7, NE; range: 1.4+, 9.1+ mo)*

Select Important Safety Information

Serious and sometimes fatal adverse reactions occurred with TECENTRIQ treatment. Warnings and precautions include severe and fatal immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, dermatologic adverse reactions, nephritis and renal dysfunction, and solid organ transplant rejection. Other warnings and precautions include infusion-related reactions, complications of allogeneic HSCT, and embryo-fetal toxicity.

Please see below and the TECENTRIQ Prescribing Information for additional Important Safety Information.

TECENTRIQ + Avastin demonstrated complete responses in 7% of patients compared to 0% with sorafenib 1

1L=first line; CI=confidence interval; CR=complete response; DoR=duration of response; HCC mRECIST=hepatocellular carcinoma modified Response Evaluation Criteria In Solid Tumors; HSCT=hematopoietic stem cell transplantation; IRF=independent review facility; mHCC=metastatic hepatocellular carcinoma; NE=not estimable; ORR=overall response rate; PR=partial response; RECIST=Response Evaluation Criteria In Solid Tumors.
*Assessed by IRF per RECIST v1.1.
Confirmed responses.